Increased expression of B7-H3 has been previously reported in multiple solid tumors, including pancreatic cancer. In a recent article, researchers from the University of Tuebingen discussed the development of a novel Fc-optimized monoclonal antibody (MAb) targeting B7-H3, named B7-H3-SDIE, as a new immunotherapeutic treatment option for pancreatic cancer.
CDR-Life Inc. has announced FDA clearance of an IND application for CDR-404, its lead program in development as a precision immunotherapy for solid tumors.
NK Celltech Co. Ltd. has announced FDA clearance for a clinical trial of NK-010, a nongenetically modified allogeneic peripheral blood natural killer (NK) cell drug.
Strand Therapeutics Inc. has received IND clearance from the FDA to initiate a first-in-human phase I trial of STX-001 as a new approach for the treatment of solid tumors.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive form of leukemia that accounts for around 25% of ALL cases. In recent years, novel strategies have emerged to reduce the dependence on intensive chemotherapy or hematopoietic stem cell transplantation, but there is still a need for new options with better efficacy in this setting.
Chulalongkorn University has divulged programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) modulators reported to be useful for the treatment of cancer.
PDC*line Pharma SA has announced the selection of the PDC*neo+ project for funding by the Walloon region of Belgium and Biowin, the health cluster for Wallonia.
Presage Biosciences Inc. has announced that the FDA has issued a study may proceed notification for testing a pre-GMP drug candidate with the company’s Comparative In Vivo Oncology (CIVO) platform. Owned by Pure Biologics, the drug candidate, PBA-0405, is a ROR1-targeting compound that has been engineered to induce tumor cell killing by cytotoxic immune cells.
RSS
